Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Rigel Pharmaceuticals, Inc.'s quarterly P/E stands at 4.9x, down 15.8% year-over-year — suggesting improving earnings relative to price.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 35.09 | 4.86 | 1.43 | 7.14 | 5.26 | 5.78 | — | — | 85.90 | — | — | — | 37.50 |
| — | -15.8% | — | — | -93.9% | — | — | — | +129.1% | — | — | — | — | |
| P/S Ratio | 3.43 | 1.95 | 0.84 | 1.53 | 1.31 | 1.29 | 0.98 | 2.19 | 1.77 | 1.67 | 2.08 | 2.20 | 1.26 |
| — | +51.3% | -14.6% | -30.2% | -25.7% | -22.9% | -53.0% | -0.1% | +39.8% | -26.5% | +27.7% | -71.4% | -77.2% | |
| P/B Ratio | 186.88 | 4.61 | 4.15 | 17.60 | 92.01 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | 19.80 | 5.65 | 2.78 | — | 5.22 | 3.29 | 450.79 | — | — | — | 9.44 | — | — |
| — | +71.5% | -99.4% | — | — | — | +4675.8% | — | — | — | — | — | — | |
| EV / EBITDA | 23.41 | 4.78 | 1.41 | 6.40 | 4.43 | 5.01 | 39.75 | — | 31.07 | — | — | — | 29.24 |
| — | -4.6% | -96.5% | — | -85.7% | — | — | — | +6.3% | — | — | — | — | |
| EV / EBIT | 25.57 | 4.70 | 1.41 | 6.40 | 4.45 | 5.08 | 42.17 | — | 26.55 | — | — | — | 27.55 |
| — | -7.4% | -96.7% | — | -83.2% | — | — | — | -3.6% | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Rigel Pharmaceuticals, Inc.'s operating margin was 40.9% in Q3 2025, down 19.2 pp QoQ and up 15.5 pp YoY. The trailing four-quarter average of 38.5% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin expanded 9.0% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 89.6% | 93.2% | 95.6% | 91.7% | 89.9% | 85.5% | 92.4% | 93.1% | 89.4% | 95.5% | 96.0% | 96.3% | 99.3% |
| — | +9.0% | +3.5% | -1.5% | +0.6% | -10.5% | -3.8% | -3.2% | -10.0% | -3.4% | -0.5% | -3.0% | +1.8% | |
| Operating Margin | 13.5% | 40.9% | 60.1% | 23.9% | 28.9% | 25.4% | 1.2% | -23.6% | 5.5% | -15.9% | -19.6% | -48.8% | 4.1% |
| — | +61.0% | +4852.6% | +201.5% | +426.5% | +260.1% | +106.2% | +51.7% | +35.5% | +80.7% | +54.9% | +68.9% | +103.9% | |
| Net Margin | 9.8% | 40.2% | 58.6% | 21.5% | 24.9% | 22.5% | -2.8% | -27.9% | 2.1% | -20.2% | -24.5% | -51.9% | 2.7% |
| — | +78.8% | +2196.9% | +176.9% | +1109.2% | +211.0% | +88.6% | +46.2% | -24.6% | +76.2% | +45.7% | +68.3% | +102.5% |
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 531.8% | 28.0% | 118.6% | 104.7% | 436.2% | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| ROA | 12.4% | 12.4% | 31.2% | 6.7% | 9.5% | 9.3% | -0.8% | -6.8% | 0.6% | -4.9% | -5.5% | -10.5% | 1.1% |
| — | +33.9% | +3955.1% | +199.5% | +1391.6% | +289.4% | +85.3% | +35.5% | -43.5% | +68.7% | +43.7% | +39.5% | +108.8% | |
| ROIC | 641.6% | 19.4% | 74.2% | 47.4% | 6138.2% | — | — | -434.8% | — | — | — | — | — |
| — | — | — | +110.9% | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Rigel Pharmaceuticals, Inc.'s Debt/EBITDA ratio is 2.1x, up from 1.0x last quarter — at a moderate level that warrants monitoring. The current ratio has improved 16.1% YoY to 2.28x, strengthening the short-term liquidity position. Debt/Equity has declined for 4 consecutive quarters, reflecting a deleveraging trend.
| Metric | TTM | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 18.24 | 0.52 | 0.75 | 3.29 | 18.24 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | 2.27 | 2.10 | 0.99 | 4.57 | 3.47 | 4.11 | 56.92 | — | 26.82 | — | — | — | 17.58 |
| — | -48.9% | -98.3% | — | -87.0% | — | — | — | +52.5% | — | — | — | — | |
| Current Ratio | 2.13 | 2.28 | 2.02 | 2.20 | 2.13 | 1.96 | 1.62 | 1.26 | 1.86 | 1.97 | 2.29 | 2.35 | 1.78 |
| — | +16.1% | +25.3% | +74.1% | +14.5% | -0.4% | -29.6% | -46.2% | +4.8% | -15.8% | +4.5% | +0.2% | -26.9% | |
| Quick Ratio | 2.04 | 2.06 | 1.90 | 2.13 | 2.04 | 1.87 | 1.48 | 1.17 | 1.76 | 1.84 | 2.05 | 2.11 | 1.64 |
| — | +9.9% | +28.9% | +81.5% | +15.9% | +1.6% | -27.8% | -44.3% | +7.5% | -15.7% | -1.6% | -5.6% | -29.6% | |
| Interest Coverage | 3.06 | 15.01 | 32.61 | 6.89 | 8.52 | 6.82 | 0.22 | -3.72 | 1.03 | -2.35 | -2.83 | -10.57 | 1.88 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare performance and metrics against top competitors.
Start ComparisonRigel Pharmaceuticals, Inc.'s current P/E is 35.1x. The average P/E over the last 4 quarters is 4.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Rigel Pharmaceuticals, Inc.'s current operating margin is 13.5%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Rigel Pharmaceuticals, Inc.'s business trajectory between earnings reports.